CN101902913B - 手术前处理 - Google Patents

手术前处理 Download PDF

Info

Publication number
CN101902913B
CN101902913B CN200880122193.0A CN200880122193A CN101902913B CN 101902913 B CN101902913 B CN 101902913B CN 200880122193 A CN200880122193 A CN 200880122193A CN 101902913 B CN101902913 B CN 101902913B
Authority
CN
China
Prior art keywords
pharmaceutical composition
application according
brimonidine
gel
surgery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200880122193.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN101902913A (zh
Inventor
杰克·A·德约文
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Galderma Laboratories LP
Original Assignee
Galderma Laboratories LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Laboratories LP filed Critical Galderma Laboratories LP
Publication of CN101902913A publication Critical patent/CN101902913A/zh
Application granted granted Critical
Publication of CN101902913B publication Critical patent/CN101902913B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
CN200880122193.0A 2007-12-21 2008-12-17 手术前处理 Expired - Fee Related CN101902913B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1591207P 2007-12-21 2007-12-21
US61/015,912 2007-12-21
PCT/US2008/013797 WO2009082452A1 (en) 2007-12-21 2008-12-17 Pre-surgical treatment

Publications (2)

Publication Number Publication Date
CN101902913A CN101902913A (zh) 2010-12-01
CN101902913B true CN101902913B (zh) 2014-06-18

Family

ID=40801507

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200880122193.0A Expired - Fee Related CN101902913B (zh) 2007-12-21 2008-12-17 手术前处理

Country Status (10)

Country Link
US (1) US20110224215A1 (OSRAM)
EP (1) EP2230910A4 (OSRAM)
JP (1) JP5580210B2 (OSRAM)
KR (1) KR20100099191A (OSRAM)
CN (1) CN101902913B (OSRAM)
AU (1) AU2008341112B2 (OSRAM)
BR (1) BRPI0822095A2 (OSRAM)
CA (1) CA2709199A1 (OSRAM)
NZ (1) NZ586302A (OSRAM)
WO (1) WO2009082452A1 (OSRAM)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US20090061020A1 (en) * 2007-08-31 2009-03-05 Theobald Klaus P Brimonidine Compositions for Treating Erythema
DK2818184T3 (en) * 2007-11-16 2019-02-25 Allergan Inc Compositions and methods for the treatment of purple
CN104324378A (zh) * 2009-05-29 2015-02-04 盖尔德马研究及发展公司 用于减少注射引起的皮肤反应的肾上腺素能受体激动剂和填充剂的可注射组合物
RU2535008C2 (ru) * 2010-03-26 2014-12-10 Галдерма Ресерч Энд Девелопмент Улучшенные способы и композиции для безопасного и эффективного лечения телеангиэктазии
BR112012024289A2 (pt) * 2010-03-26 2017-07-18 Galderma Res & Dev "método para fornecer um tratamento seguro e efetivo do eritema e composição de gel tópica"
FR2966365B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel topique
US8053427B1 (en) 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
JP2013540142A (ja) * 2010-10-21 2013-10-31 ガルデルマ・ソシエテ・アノニム 局所ゲル組成物
FR2966366B1 (fr) * 2010-10-21 2012-11-09 Galderma Sa Composition de gel de brimonidine
BR112013009578B1 (pt) * 2010-10-21 2020-10-20 Galderma S.A. composição tópica em gel e uso de uma composição tópica em gel
FR2977493B1 (fr) * 2011-07-05 2014-02-14 Galderma Res & Dev Nouvelle composition anesthesique stable pour la reduction des reactions cutanees
BR112014009210A2 (pt) 2011-10-19 2017-04-18 Galderma Sa método para a redução da vermelhidão facial cutânea
JP6339364B2 (ja) * 2013-12-27 2018-06-06 カズマパートナーズ株式会社 無定形ブリモニジン酒石酸塩及びその製造方法
CA3079824A1 (en) * 2017-10-23 2019-05-02 Microcures, Inc. Method for enhancing recovery of cosmetic laser-treated skin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2003198C (en) 1988-11-29 1995-03-21 Anthony J. Dziabo, Jr. Aqueous ophthalmic solutions and method for preserving same
US5736165A (en) 1993-05-25 1998-04-07 Allergan In-the-eye use of chlorine dioxide-containing compositions
US6194415B1 (en) 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
CA2154979A1 (en) * 1995-07-28 1997-01-29 Kenneth T. Armstrong Topical phenylephrine preparation
US7973068B2 (en) * 1998-10-20 2011-07-05 Omeros Corporation Arthroscopic irrigation solution and method for peripheral vasoconstriction and inhibition of pain and inflammation
US6294553B1 (en) * 2000-02-15 2001-09-25 Allergan Sales, Inc. Method for treating ocular pain
US6468989B1 (en) 2000-07-13 2002-10-22 Dow Pharmaceutical Sciences Gel compositions containing metronidazole
US6387383B1 (en) 2000-08-03 2002-05-14 Dow Pharmaceutical Sciences Topical low-viscosity gel composition
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
DK2818184T3 (en) * 2007-11-16 2019-02-25 Allergan Inc Compositions and methods for the treatment of purple

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Effect of Prophylactic Brimonidine Instillation on Bleeding During Strabismus Surgery in Adults;Samin Hong, et al.;《AMERICAN JOURNAL OF OPHTHALMOLOGY》;20070930;第144卷(第3期);第469-470页 *

Also Published As

Publication number Publication date
KR20100099191A (ko) 2010-09-10
CA2709199A1 (en) 2009-07-02
BRPI0822095A2 (pt) 2014-10-07
AU2008341112B2 (en) 2014-02-06
EP2230910A4 (en) 2011-04-13
JP5580210B2 (ja) 2014-08-27
JP2011507845A (ja) 2011-03-10
WO2009082452A1 (en) 2009-07-02
US20110224215A1 (en) 2011-09-15
AU2008341112A1 (en) 2009-07-02
CN101902913A (zh) 2010-12-01
EP2230910A1 (en) 2010-09-29
NZ586302A (en) 2013-03-28

Similar Documents

Publication Publication Date Title
CN101902913B (zh) 手术前处理
JP5670196B2 (ja) 紫斑を治療する組成物および方法
WO2009032223A1 (en) Improved brimonidine compositions for treating erythema
US8633181B2 (en) Treatment of cutaneous hemangioma
JP2016525553A (ja) 皮膚肥厚の治療法
US20140329874A1 (en) Alpha adrenergic agonists for the treatment of tissue trauma
AU2012324544B2 (en) Method for treating capillary hemangiomas
CN105658221B (zh) 用于治疗萎缩性皮肤瘢痕形成的前列腺素F2α及其类似物
CN113440483B (zh) 一种犬用盐酸特比萘芬喷剂及其制备方法
HK1177102A (en) Methods of treating or preventing acute erythema

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140618

Termination date: 20171217